Title |
Roxithromycin monotherapy inducing a partial response in a patient with myeloma: a case report
|
---|---|
Published in |
Journal of Medical Case Reports, May 2018
|
DOI | 10.1186/s13256-018-1636-9 |
Pubmed ID | |
Authors |
Kern Y. Chai, Anna L. Byrne, Ian M. Morison |
Abstract |
Clarithromycin is an efficacious treatment for myeloma in combination with other anti-myeloma therapy but not as monotherapy. To date, all studies have focused on a clarithromycin-specific effect rather than a class effect (macrolide) and there is no information on the activity of roxithromycin in myeloma. Here we report an untreated 86-year-old New Zealand European white man with IgA myeloma whose paraprotein decreased by 57%, consistent with a partial response, after a course of roxithromycin for pneumonia. His paraprotein reduced from 46 to 20 g/L while his hemoglobin improved from 97 to 123 g/L after 1 month. Additional investigations should be considered to elucidate the therapeutic effect of roxithromycin in myeloma. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 67% |
New Zealand | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 2 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 5 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 2 | 40% |
Professor | 1 | 20% |
Unknown | 2 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 60% |
Unknown | 2 | 40% |